Inhibitors of kynurenine hydroxylase and kynureninase increase cerebral formation of kynurenate and have sedative and anticonvulsant activities.

Kynurenate is an endogenous antagonist of the ionotropic glutamate receptors. It is synthesized from kynurenine, a tryptophan metabolite, and a significant increase in its brain concentration could be useful in pathological situations. We attempted to increase its neosynthesis by modifying kynurenine catabolism. Several kynurenine analogues were synthesized and tested as inhibitors of kynurenine hydroxylase (E.C.1.14.13.9) and of kynureninase (E.C.3.7.1.3), the two enzymes which catalyse the conversion of kynurenine to excitotoxin quinolinate. Among these analogues we observed that nicotinylalanine, a compound whose pharmacological properties have previously been reported, had an IC50 of 900 +/- 180 microM as inhibitor of kynurenine hydroxylase and of 800 +/- 120 microM as inhibitor of kynureninase. In the search for more potent molecules we noticed that meta-nitrobenzoylalanine had an IC50 of 0.9 +/- 0.1 microM as inhibitor of kynurenine hydroxylase and of 100 +/- 12 microM as inhibitor of kynureninase. When administered to rats meta-nitrobenzoylalanine (400 mg/kg) significantly increased the concentration of kynurenine (up to 10 times) and kynurenate (up to five times) in the brain. Similar results were obtained in the blood and in the liver. Furthermore meta-nitrobenzoylalanine increased in a dose dependent, long lasting (up to 13 times and up to 4 h) manner the concentration of kynurenate in the hippocampal extracellular fluid, as evaluated with a microdialysis technique. This increase was associated with a decrease in the locomotor activity and with protection from maximal electroshock-induced seizures in rats or from audiogenic seizures in DBA/2 mice. The conclusions drawn from the present study are: (i) meta-nitrobenzoylalanine is a potent inhibitor of kynurenine hydroxylase also affecting kynureninase; (ii) the inhibition of these enzymes causes a significant increase in the brain extracellular concentration of kynurenate; (iii) this increase is associated with sedative and anticonvulsant actions, suggesting a functional antagonism of the excitatory amino acid receptors.

Nicotinylalanine increases the formation of kynurenic acid in the brain and antagonizes convulsions.

Kynurenic acid (KYNA) was quantified in the extracellular spaces of the rat hippocampus using microdialysis and HPLC (fluorimetric detection) to study the possible role of this tryptophan metabolite in the modulation of the function of the N-methyl-D-aspartate (NMDA) receptor. Addition of probenecid (1 mM), which is an inhibitor of the organic acid transport system, to the Ringer's solution perfusing the dialysis probe increased the KYNA concentration in the dialysate from 10.4 +/- 0.9 to 48 +/- 6 nM. Addition of 2 mM aminooxyacetic acid, a nonspecific inhibitor of KYNA synthesis, reduced this concentration by 50%. These data suggest that KYNA is continuously synthesized in the rat hippocampus. Nicotinylalanine (NAL), 200-400 mg/kg i.p., an analogue of kynurenine that is able to direct the flow of tryptophan metabolites toward the synthesis of KYNA, significantly increased the KYNA concentration in the hippocampal dialysate and significantly potentiated the effect of tryptophan on the accumulation of KYNA in the brain and other organs. This increase resulted in pharmacological actions compatible with an antagonism of the NMDA receptors. In fact, NAL antagonized sound-induced seizures and prevented death in DBA/2 mice. Pretreatment of the mice with D-serine (100 micrograms intracerebroventricularly), a glycine agonist and a competitive antagonist of KYNA, completely prevented the anticonvulsive action of NAL. These data suggest that changes in the extracellular concentration of KYNA in the brain are associated with a modulation of NMDA receptor function.

Modulation of quinolinic and kynurenic acid content in the rat brain: effects of endotoxins and nicotinylalanine.

Quinolinic acid, an endogenous excitotoxin, and kynurenic acid, an antagonist of excitatory amino acid receptors, are believed to be synthesized from tryptophan after the opening of the indole ring. They were measured in the rat brain and other organs using gas chromatography-mass spectrometry or HPLC. The enzyme indoleamine 2,3-dioxygenase, capable of cleaving the indole ring of tryptophan, was induced by administering bacterial endotoxins to rats, which significantly increased the brain content of both quinolinic and kynurenic acids. Nicotinylalanine, an analogue of kynurenine, inhibited this endotoxin-induced accumulation of quinolinic acid while potentiating the accumulation of kynurenic acid. The possibility of significantly increasing brain concentrations of kynurenic acid without a concomitant increase in quinolinic acid may provide a useful approach for studying the role of these electrophysiologically active tryptophan metabolites in brain function and preventing the possible toxic actions of abnormal synthesis of quinolinic acid.

Indolpyruvic acid administration increases the brain content of kynurenic acid. Is this a new avenue to modulate excitatory amino acid receptors in vivo?

The possibility of changing the tissue content of kynurenic acid (KYNA), a tryptophan metabolite which acts as an antagonist of the excitatory amino acid receptors, was investigated by measuring its concentration in the brain, blood, liver and kidney of rats using a specific method based on ion exchange chromatography and HPLC. The administration of tryptophan (TRP) or of its keto analogue, indolpyruvic acid (IPA) (50-500 mg/kg i.p.), significantly increased, in a dose-dependent manner, the content of KYNA in various organs, including the brain. The increased brain content of KYNA after IPA administration could not be completely explained by considering that IPA may be transaminated to TRP and that the enzymes leading from TRP to KYNA are known. An alternative pathway of KYNA synthesis from IPA was therefore proposed. These findings indicate that it is possible to change the brain content of an endogenous glutamate antagonist. This could be a new avenue to modulate in vivo excitatory amino acid receptors.

Kynurenic acid is present in the rat brain and its content increases during development and aging processes.

The content of kynurenic acid, a tryptophan (TRP) metabolite which acts as an antagonist of the excitatory amino acid receptors, was measured in the brain, blood, liver and kidney of rats of different ages, using a sensitive and specific method based on ion exchange chromatography and high-performance liquid chromatography (HPLC). In a portion of the cortex of these animals the content of serotonin (5-HT), 5-hydroxyindole-3-acetic acid (5-HIAA) and of TRP was also measured using HPLC and electrochemical detection. The brain content of kynurenic acid was extremely low during the first week of life measuring 15 +/- 3 pmol/g protein (mean +/- S.E.M.), was found to be 320 +/- 31 at 3 months and continued to increase reaching levels of 747 +/- 116 at 18 months of age. Aging failed to change kynurenate content in the liver and kidney while blood kynurenate concentration increased from 28 +/- 5 (pmol/ml) in 3 months old rats to 65 +/- 10 in those 18 months old. The accumulation of kynurenate in the brain was not due to an increased availability of TRP to the central nervous system of aged rats. In fact, the cortical content of this amino acid was slightly lower in animals 18 months old than in those 3 months old. These large changes of the brain content of an electrophysiologically active TRP metabolite such as kynurenic acid could help explain the functional differences present in the brain of newborn and aged animals.

Presence of kynurenic acid in the mammalian brain.

Kynurenic acid, a tryptophan metabolite able to antagonize the actions of the excitatory amino acids, has been identified and measured for the first time in the brain of mice, rats, guinea pigs, and humans by using an HPLC method. Its content was 5.8 +/- 0.9 in mouse brain, 17.8 +/- 2.0 in rat brain, 16.2 +/- 1.5 in guinea pig brain, 26.8 +/- 2.9 in rabbit brain, and 150 +/- 30 in human cortex (pmol/g wet wt. mean +/- SE). The regional distribution of this molecule was uneven. In rats, guinea pigs, and rabbits, the brainstem was the area richest in this compound. Tryptophan administration (100-300 mg/kg, i.p.) to rats resulted in a significant increase of the brain content of kynurenic acid. Similarly, 1 h after probenecid administration (200 mg/kg, i.p.), the brain content of kynurenate increased by fourfold, thus suggesting that its turnover rate is relatively fast.

Identification and measurement of kynurenic acid in the rat brain and other organs.

Kynurenic acid, a biologically active tryptophan metabolite, has been identified and measured in the rat brain and other organs using HPLC and GC/MS. Both the described methods required extraction of the compound in alkaline ethanol and initial purification on Dowex ion-exchange resins. The GC/MS approach used 3-hydroxy-2-naphthoic acid as an internal standard and a derivatization procedure with diazomethane and trifluoroacetic anhydride. The HPLC procedure was performed on a reverse-phase column using a spectrophotometric detector. Both the GC/MS and the HPLC methods had the lowest detection limit in the range of 10 pmol/injection, but the variability of the results was lower when HPLC was used. HPLC analysis showed the content of kynurenic acid to be 14 +/- 2 pmol/g wet wt in the brain, 75 +/- 7 in the heart, 87 +/- 8 in the liver, and 298 +/- 10 in the kidneys. Comparable but variable values were obtained with GC/MS.